59 related articles for article (PubMed ID: 38459598)
21. Molecular imaging of HER2 expression in breast cancer patients using a novel peptide-based tracer
Shi J; Du S; Wang R; Gao H; Luo Q; Hou G; Zhou Y; Zhu Z; Wang F
J Transl Med; 2023 Jan; 21(1):19. PubMed ID: 36631812
[TBL] [Abstract][Full Text] [Related]
22. High in-vivo stability in preclinical and first-in-human experiments with [
Qin X; Guo X; Liu T; Li L; Zhou N; Ma X; Meng X; Liu J; Zhu H; Jia B; Yang Z
Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):302-313. PubMed ID: 36129493
[TBL] [Abstract][Full Text] [Related]
23. HER2-targeted dual radiotracer approach with clinical potential for noninvasive imaging of trastuzumab-resistance caused by epitope masking.
Li L; Liu T; Shi L; Zhang X; Guo X; Hu B; Yao M; Zhu H; Yang Z; Jia B; Wang F
Theranostics; 2022; 12(12):5551-5563. PubMed ID: 35910795
[No Abstract] [Full Text] [Related]
24. Targeting HER2 heterogeneity in breast cancer.
Hamilton E; Shastry M; Shiller SM; Ren R
Cancer Treat Rev; 2021 Nov; 100():102286. PubMed ID: 34534820
[TBL] [Abstract][Full Text] [Related]
25. Phase I Trial of
Bragina O; Chernov V; Schulga A; Konovalova E; Garbukov E; Vorobyeva A; Orlova A; Tashireva L; Sörensen J; Zelchan R; Medvedeva A; Deyev S; Tolmachev V
J Nucl Med; 2022 Apr; 63(4):528-535. PubMed ID: 34385343
[TBL] [Abstract][Full Text] [Related]
26. Development of a
Zhao L; Liu C; Xing Y; He J; O'Doherty J; Huang W; Zhao J
Mol Pharm; 2021 Sep; 18(9):3616-3622. PubMed ID: 34328338
[TBL] [Abstract][Full Text] [Related]
27. Preclinical Evaluation of
Oroujeni M; Rinne SS; Vorobyeva A; Loftenius A; Feldwisch J; Jonasson P; Chernov V; Orlova A; Frejd FY; Tolmachev V
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803361
[TBL] [Abstract][Full Text] [Related]
28. The emerging role of radionuclide molecular imaging of HER2 expression in breast cancer.
Tolmachev V; Orlova A; Sörensen J
Semin Cancer Biol; 2021 Jul; 72():185-197. PubMed ID: 33465471
[TBL] [Abstract][Full Text] [Related]
29. Phase I Trial of
D'Huyvetter M; Vos J; Caveliers V; Vaneycken I; Heemskerk J; Duhoux FP; Fontaine C; Vanhoeij M; Windhorst AD; Aa FV; Hendrikse NH; Eersels JLE; Everaert H; Gykiere P; Devoogdt N; Raes G; Lahoutte T; Keyaerts M
J Nucl Med; 2021 Aug; 62(8):1097-1105. PubMed ID: 33277400
[No Abstract] [Full Text] [Related]
30. Targeting and imaging of HER2 overexpression tumor with a new peptide-based
Biabani Ardakani J; Akhlaghi M; Nikkholgh B; Hosseinimehr SJ
Bioorg Chem; 2021 Jan; 106():104474. PubMed ID: 33246602
[TBL] [Abstract][Full Text] [Related]
31. HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging.
Altunay B; Morgenroth A; Beheshti M; Vogg A; Wong NCL; Ting HH; Biersack HJ; Stickeler E; Mottaghy FM
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1371-1389. PubMed ID: 33179151
[TBL] [Abstract][Full Text] [Related]
32. Peptide Based Imaging Agents for HER2 Imaging in Oncology.
Ducharme M; Lapi SE
Mol Imaging; 2020; 19():1536012120960258. PubMed ID: 32957830
[TBL] [Abstract][Full Text] [Related]
33. Phase I Study of
Bragina O; von Witting E; Garousi J; Zelchan R; Sandström M; Orlova A; Medvedeva A; Doroshenko A; Vorobyeva A; Lindbo S; Borin J; Tarabanovskaya N; Sörensen J; Hober S; Chernov V; Tolmachev V
J Nucl Med; 2021 Apr; 62(4):493-499. PubMed ID: 32817142
[TBL] [Abstract][Full Text] [Related]
34. Preclinical Targeted α- and β
Puttemans J; Dekempeneer Y; Eersels JL; Hanssens H; Debie P; Keyaerts M; Windhorst AD; van der Aa F; Lecocq Q; Breckpot K; Morgenstern A; Bruchertseifer F; Lahoutte T; Devoogdt N; D'Huyvetter M
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32326199
[TBL] [Abstract][Full Text] [Related]
35. Imaging and monitoring HER2 expression in breast cancer during trastuzumab therapy with a peptide probe
Wu Y; Li L; Wang Z; Shi J; Hu Z; Gao S; Miao W; Ma Q; Dong C; Wang F
Eur J Nucl Med Mol Imaging; 2020 Oct; 47(11):2613-2623. PubMed ID: 32170344
[TBL] [Abstract][Full Text] [Related]
36. Towards personalized treatment for early stage HER2-positive breast cancer.
Goutsouliak K; Veeraraghavan J; Sethunath V; De Angelis C; Osborne CK; Rimawi MF; Schiff R
Nat Rev Clin Oncol; 2020 Apr; 17(4):233-250. PubMed ID: 31836877
[TBL] [Abstract][Full Text] [Related]
37. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Murthy RK; Loi S; Okines A; Paplomata E; Hamilton E; Hurvitz SA; Lin NU; Borges V; Abramson V; Anders C; Bedard PL; Oliveira M; Jakobsen E; Bachelot T; Shachar SS; Müller V; Braga S; Duhoux FP; Greil R; Cameron D; Carey LA; Curigliano G; Gelmon K; Hortobagyi G; Krop I; Loibl S; Pegram M; Slamon D; Palanca-Wessels MC; Walker L; Feng W; Winer EP
N Engl J Med; 2020 Feb; 382(7):597-609. PubMed ID: 31825569
[TBL] [Abstract][Full Text] [Related]
38. HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation.
Ahn S; Woo JW; Lee K; Park SY
J Pathol Transl Med; 2020 Jan; 54(1):34-44. PubMed ID: 31693827
[TBL] [Abstract][Full Text] [Related]
39. Loss of HER2 after HER2-targeted treatment.
Ignatov T; Gorbunow F; Eggemann H; Ortmann O; Ignatov A
Breast Cancer Res Treat; 2019 Jun; 175(2):401-408. PubMed ID: 30806922
[TBL] [Abstract][Full Text] [Related]
40. Nanobody: outstanding features for diagnostic and therapeutic applications.
Salvador JP; Vilaplana L; Marco MP
Anal Bioanal Chem; 2019 Mar; 411(9):1703-1713. PubMed ID: 30734854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
